Simultaneous hyperpolarized 13C-pyruvate MRI and 18F-FDG-PET in cancer (hyperPET)
feasibility of a new imaging concept using a clinical PET/MRI scanner

Borgwardt, Henrik Gutte; Hansen, Adam Espe; Henriksen, Sarah T.; Johannesen, Helle Hjorth; Ardenkjær-Larsen, Jan Henrik; Vignaud, Alexandre; Hansen, Anders Elias; Børresen, Betina; Klausen, Thomas Levin; Wittekind, Anne-Mette N.; Gillings, Nic; Kristensen, Annemarie Thuri; Clemmensen, Andreas Ettrup; Højgaard, Liselotte; Kjær, Andreas

Published in:
American Journal of Nuclear Medicine and Molecular Imaging

Publication date:
2015

Document version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Original Article

Simultaneous hyperpolarized $^{13}$C-pyruvate MRI and $^{18}$F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner

Henrik Gutte$^{1,2}$, Adam E Hansen$^{1}$, Sarah T Henriksen$^{1,3}$, Helle H Johannessen$^{1}$, Jan Ardenkjaer-Larsen$^{3,4}$, Alexandre Vignaud$^{5}$, Anders E Hansen$^{2,6}$, Betina Børresen$^{7}$, Thomas L Klausen$^{1}$, Anne-Mette N Wittekind$^{1}$, Nic Gillings$^{1}$, Annemarie T Kristensen$^{7}$, Andreas Clemmensen$^{1,2}$, Liselotte Højgaard$^{1}$, Andreas Kjær$^{1,2}$

$^1$Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Denmark; $^2$Cluster for Molecular Imaging, Faculty of Health Sciences, University of Copenhagen, Denmark; $^3$Department of Electrical Engineering, Technical University of Denmark, Lyngby, Denmark; $^4$GE Healthcare, Brøndby, Denmark; $^5$CEA Saclay, I2BM, NeuroSpin, UNIRS, Gif sur Yvette, France; $^6$Center for Nanomedicine and Theranostics, Technical University of Denmark, Denmark; $^7$Department of Veterinary Clinical and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C, Denmark. *Equal contributors.

Received September 14, 2014; Accepted September 29, 2014; Epub December 15, 2014; Published January 1, 2015

Abstract: In this paper we demonstrate, for the first time, the feasibility of a new imaging concept - combined hyperpolarized $^{13}$C-pyruvate magnetic resonance spectroscopic imaging (MRSI) and $^{18}$F-FDG-PET imaging. This procedure was performed in a clinical PET/MRI scanner with a canine cancer patient. We have named this concept hyper PET. Intravenous injection of the hyperpolarized $^{13}$C-pyruvate results in an increase of $^{13}$C-lactate, $^{13}$C-alanine and $^{13}$C- CO$_3$ ($^{13}$C-HCO$_3$) resonance peaks relative to the tissue, disease and the metabolic state probed. Accordingly, with dynamic nuclear polarization (DNP) and use of $^{13}$C-pyruvate it is now possible to directly study the Warburg Effect through the rate of conversion of $^{13}$C-pyruvate to $^{13}$C-lactate. In this study, we combined it with $^{18}$F-FDG-PET that studies uptake of glucose in the cells. A canine cancer patient with a histology verified local recurrence of a liposarcoma on the right forepaw was imaged using a combined PET/MR clinical scanner. PET was performed as a single-bed, 10 min acquisition, 107 min post injection of 310 MBq $^{18}$F-FDG. $^{13}$C-chemical shift imaging (CSI) was performed just after FDG-PET and 30 s post injection of 23 mL hyperpolarized $^{13}$C-pyruvate. Peak heights of $^{13}$C-pyruvate and $^{13}$C-lactate were quantified using a general linear model. Anatomic $^{1}$H-MRI included axial and coronal T1 vibe, coronal T2-tse and axial T1-tse with fat saturation following gadolinium injection. In the tumor we found clearly increased $^{13}$C-lactate production, which also corresponded to high $^{18}$F-FDG uptake on PET. This is in agreement with the fact that glycolysis and production of lactate are increased in tumor cells compared to normal cells. Yet, most interestingly, also in the muscle of the forepaw of the dog high $^{18}$F-FDG uptake was observed. This was due to activity in these muscles prior to anesthesia, which was not accompanied by a similarly high $^{13}$C-lactate production. Accordingly, this clearly demonstrates how the Warburg Effect directly can be demonstrated by hyperpolarized $^{13}$C-pyruvate MRSI. This was not possible with $^{18}$F-FDG-PET imaging due to inability to discriminate between causes of increased glucose uptake. We propose that this new concept of simultaneous hyperpolarized $^{13}$C-pyruvate MRSI and PET may be highly valuable for image-based non-invasive phenotyping of tumors. This methods may be useful for treatment planning and therapy monitoring.

Keywords: Cancer, DNP, hyperpolarized, $^{13}$C-pyruvate, MR, response monitoring, $^{18}$F-FDG-PET, PET/MR, molecular imaging

Introduction

Traditionally, staging and anti-cancer therapy monitoring has been performed by morphological imaging methods. CT imaging applying RECIST criteria or similar criteria, has been the standard method [1]. Where CT is of less sensitive, e.g. brain and prostate tumors, morphological proton MRI is largely applied [2, 3]. However, recently it has been acknowledged that imaging methods visualizing tumor phenotype may be of greater value [4, 5]. Especially visualization of metabolism, one of the hallmarks of cancer, has drawn attention as a most
Hyperpolarized $^{13}$C-pyruvate and $^{18}$F-FDG-PET in cancer

A key metabolic fingerprint in cancer cells is the switch to glycolysis with production of lactate even in the presence of sufficient oxygen [9-12], as illustrated in Figure 1. This phenomenon was first described by Heinrich Otto Warburg in 1924 and has since been named the Warburg effect [13, 14]. Since glucose metabolism in normal non-hypoxic cells through oxidative phosphorylation is much more effective than aerobic glycolysis, much higher amounts of glucose is utilized in cancer cells (10-20 fold) even if these cells do not have a higher energy need.

To further characterize tumors phenotypically, methods specifically looking at the metabolic pathways of value. Magnetic Resonance Spectroscopy (MRS) is a technique that offers non-invasive in vivo assessment of tissue chemistry and cellular metabolism [18]. However, the low sensitivity of MRS has limited its use for this. Recently, development of the technique of Dynamic Nuclear Polarization (DNP) circumvented this elegantly. DNP is capable of creating solutions of molecules with polarized nuclear spins in various nuclei and has enabled real-time investigation of in vivo metabolism. The development of this new method has enhanced the nuclear polarization more than 10,000-fold, thereby significantly increasing the sensitivity of MRS [19]. Furthermore, the method enables measuring the kinetics of the conversion of the substrate into other cell metabolites and can be combined with anatomical proton MRI. Different nuclei have been hyperpolarized...
Hyperpolarized $^{13}$C-pyruvate and $^{18}$F-FDG-PET in cancer

Using the DNP method. Currently, the most widely used nucleus has been $^{13}$C due to favoring characteristics and the possibility of incorporating $^{13}$C into biologically relevant compounds, e.g., pyruvate. Intravenous injection of hyperpolarized $^{13}$C-pyruvate results in the increase of $^{13}$C-lactate, $^{13}$C-alanine and $^{13}$C-CO$_2$ ($^{13}$C-HCO$_3^-$) resonance peaks relative to the tissue, disease and the metabolic state probed [19, 20]. Figure 2 illustrates the cell metabolism of $^{13}$C-pyruvate. Accordingly, with DNP and use of $^{13}$C-pyruvate it is now possible to directly study the Warburg effect through the rate of conversion from $^{13}$C-pyruvate to $^{13}$C-lactate [21, 22].

The aim of our study was therefore to demonstrate, for the first time, the feasibility of simultaneous in vivo PET combined with hyperpolarized MRI. Specifically, we aimed to show that $^{18}$F-FDG-PET could be combined with $^{13}$C-pyruvate magnetic resonance spectroscopic imaging (MRSI) for characterization of cancer using a clinical PET/MRI scanner.

Methods

A canine cancer patient (female Labrador Retriever, 32 kg) with a biopsy-verified local recurrence of a liposarcoma on the right ante brachium was the test subject. Imaging was performed using a combined PET/MR clinical scanner (Siemens mMR Biograph, Siemens, Erlangen, Germany). The liposarcoma had been irradiated two years prior to recurrence (4 fractions) and surgically removed. The dog was premedicated with Methadone (0.2 mg/kg IM) and anaesthetized using a bolus injection of Propofol. Anesthesia was maintained by a continuous intravenous infusion of Propofol (15-25 mg/kg/h). Heart rate, oxygen saturation, and blood pressure were measured throughout the scanning procedure. In the periphery of the lesion, fish oil capsules were placed for better delineation of the tumor on the localizers datasets. The dog was placed in prone position head-first. MRI utilized a dual tuned flex coil (RAPID Biomedical, Rimpar, Germany). A 5.5 mL vial of 4.0 M $^{13}$C-urea mixed with Gadolinium (Dotarem, GUERBET, Roissy, France) at the back of the coil was used for MR flip angle calibration and frequency centering. The coil was placed above the front leg and centered on the lesion.

The study was approved by The Ethics and Administrative Committee, Department of Clinical Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen.

Hyperpolarized $^{13}$C-pyruvate

Hyperpolarized $^{13}$C-pyruvate was prepared using the SpinLab system (GE Healthcare, Milwaukee, WI, USA). The $^{13}$C-pyruvate sample consisted of [1-$^{13}$C]pyruvic acid mixed with an Electron Paramagnetic Agent (EPA) manufactured by Syncom (Groningen, Netherlands, PN AH111501. The EPA concentration in the sample is 15 mM. The dissolution media applied contains 0.1 g/L ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA disodium salt, Sigma PN E4994) in water. The neutralization media used to neutralize the hyperpolarized [1-$^{13}$C]pyruvic acid sample prior to injection contains 0.72 M NaOH, 0.4 M Tris and 0.1 g/L EDTA disodium salt in water.
Hyperpolarized $^{13}$C-pyruvate and $^{18}$F-FDG-PET in cancer

$^{1}$H-MR-imaging

Localizer images and manual $^{13}$C flip angle calibration was followed by anatomic $^{1}$H-MRI, including axial T1 vibe and coronal T2-tse. In an axial-oblique 40 mm thick slab including the tumor region, dynamic $^{13}$C-MRS was performed. Parameters were repetition time (TR) $1,000 \text{ ms}$, echo time (TE) $0.757 \text{ ms}$, flip angle $5^\circ$, bandwidth $4,000 \text{ Hz}$. The acquisition was repeated 180 times, commencing at the injection of the hyperpolarized $^{13}$C-pyruvate (23 mL).

$^{18}$F-FDG imaging

PET was performed as a single-bed, 10 min acquisition, 107 min post iv injection of 310 MBq $^{18}$F-FDG. Image reconstruction was performed using 3D OP-OSEM 4(21s), matrix 344, 4 mm Gaussian post-filter and vendor supplied attenuation correction algorithms.

$^{13}$C-chemical shift imaging

$^{13}$C-chemical shift imaging (CSI) was undertaken just after $^{18}$F-FDG-PET and 30 s post injection of 23 mL hyperpolarized $^{13}$C-pyruvate (250 mM). Parameters were repetition time $80 \text{ ms}$, flip angle $23^\circ$, bandwidth $10,000 \text{ Hz}$, FOV 80 mm, slice thickness 23 mm, matrix 16x16 (circular truncation) and total imaging time 11 s. The 30 s delay was chosen to obtain maximum $^{13}$C-lactate signal during imaging based on the previous dynamic $^{13}$C-MRS acquisition. Finally, axial T1-tse MRI with fat saturation was performed following gadolinium injection (6.4 mL Dotarem). Peak heights of $^{13}$C-pyruvate, $^{13}$C-citrate, $^{13}$C-alanine and $^{13}$C-pyruvate hydrate were quantified using a general linear model implemented in Matlab (MathWorks, Natick, MA, USA). A set of additional components were included in the model to account for frequency shifts and peak splitting of the $^{13}$C-pyruvate and $^{13}$C-lactate peak observed in voxels containing vascular tissue. Further, the first and second derivatives of all metabolites were included in the model. The estimation was performed in the frequency domain on baseline corrected spectra. We report the ratio of $^{13}$C-lactate normalized to the sum of all modeled peak heights.

Results

Work-flow

We found that combined FDG-PET and $^{13}$C-pyruvate MRSI was feasible in a single session of approximately 2 h. A continuous work-flow was obtained with start of hyperpolarization of $^{13}$C-pyruvate and injection of FDG-PET almost at the same time. After approximately 1½ h a

Figure 3. Coronal $^{18}$F-FDG-PET/MR images of right front leg showing the liposarcoma (arrow). Note the high concentration of $^{18}$F-FDG in the muscle. A: $^{18}$F-FDG-PET. B: $T_2$-TSE + $^{18}$F-FDG-PET. C: $T_2$-TSE.
10 min FDG-PET acquisition was performed that was immediately followed by dissolution and injection of $^{13}$C-pyruvate that took less than 30 s in our setup. Acquisition of $^{13}$C-lactate and $^{13}$C-pyruvate spectra lasted less than 2 min. $^1$H-MR-imaging was performed between FDG injection and FDG-PET acquisition.

$^1$H-MRI

The tumor was easily delineated on $^1$H-MRI as clearly seen on the coronal images (Figure 3).

$^{18}$F-FDG imaging

On both coronal and transaxial images a high uptake of $^{18}$F-FDG in the tumor (liposarcoma) was observed. Furthermore, also in muscles a clear uptake of $^{18}$F-FDG was seen (Figures 3 and 4). Quantification of $^{18}$F-FDG uptake in the tumor revealed a SUV$_{max}$ of 1.52 the transaxial slice where $^{13}$C-chemical shift imaging was performed (Figure 4). For muscle the SUV$_{max}$ in the same slice was found to be almost as high, namely 1.26 (Figure 4).

$^{13}$C-chemical shift imaging (CSI)

Initially a dynamic $^{13}$C-MRS was performed (Figure 5). The dynamic MRS showed a large peak 10 s after the injection of the $^{13}$C-pyruvate. This initial peak was followed by generation of $^{13}$C-lactate, with the peak concentration appearing approximately 40 s after injection.

Figure 4. Transaxial images of right front leg showing the liposarcoma. Note the high concentration of $^{18}$F-FDG in muscle (arrow, panel B, $^{18}$F-FDG-PET + $^1$H-MRI) and of $^{13}$C-pyruvate in the large vessels (arrow in panel D, $^{13}$C-Pyruvate CSI + $^1$H-MRI). A: $^{18}$F-FDG-PET. B: $^{18}$F-FDG-PET + $^1$H-MRI. C: $^1$H-MRI. D: $^{13}$C-Pyruvate CSI + $^1$H-MRI. E: $^{13}$C-lactate CSI + $^1$H-MRI.

Figure 5. The dynamic $^{13}$C-MRS showed initially a large peak 10 s after the injection of the $^{13}$C-pyruvate. This was followed by generation of $^{13}$C-lactate, with the peak concentration appearing approximately 40 s after injection.
Hyperpolarized $^{13}$C-pyruvate and $^{18}$F-FDG-PET in cancer

was observed in the tumor (Figure 4E). Calculation of the $^{13}$C-lactate/$^{13}$C-pyruvate ratio revealed a ratio of 0.213 in the tumor, 0.078 in the muscle and 0.038 in the vasculature (Figure 4). The tumor area with highest $^{13}$C-lactate/$^{13}$C-pyruvate ratio also had the highest $^{18}$F-FDG uptake. In Figure 6 $^{13}$C-MRS of a single voxel encompassed in the tumor is shown. Note that $^{13}$C-lactate and $^{13}$C-pyruvate are clearly seen as distinct peaks.

Discussion

To our knowledge this is the first study acquiring both $^{13}$C-lactate/$^{13}$C-pyruvate CSI and $^{18}$F-FDG-PET using a combined clinical PET/MR scanner. We found that this new concept, hyperPET, simultaneous hyperpolarized $^{13}$C-pyruvate MRSI and $^{18}$F-FDG-PET, is feasible and may be a highly valuable tool for image-based characterization of tumors in vivo. In our study we were able to visualize in real time the metabolism of $^{13}$C-pyruvate and conversion into $^{13}$C-lactate in a spontaneous canine liposarcoma. In the tumor we found clearly $^{13}$C-lactate production, which also corresponded to high $^{18}$F-FDG uptake on PET. This is in agreement with the well-know fact that glycolysis and production of lactate are increased in tumor cells compared to normal cells [4]. However, most interestingly also in the muscle of the forepaw of the dog, high $^{18}$F-FDG uptake was observed due to use of these muscles prior to anesthesia but this was not accompanied by a similarly high $^{13}$C-lactate production. Accordingly, this clearly demonstrates how the Warburg effect is specifically shown by $^{13}$C-pyruvate MRSI whereas $^{18}$F-FDG was not capable of this and cannot discriminate between whether glucose uptake is increased due to oxidative phosphorylation operating at a high level or due to glycolysis.

In our study, we used a canine cancer patient with a spontaneous syngeneic cancer as it mirrors biological behavior of human cancer including heterogeneity, microenvironment, mode of progression, metastasis etc.. Accordingly, cancer bearing dogs represent a unique clinical cancer model with a direct potential for facilitating translation of results to human patients [23].

Technically, a simple CSI technique was employed for spectroscopic imaging in the current study. More advanced techniques allow for faster, volumetric and repeated spectroscopic imaging (for review, see [24, 25]). Such techniques therefore permit for larger spatial coverage and more detailed characterization of the tumor metabolism. We aim at implementing these techniques in future studies.

The use of hyperpolarized $^{13}$C-pyruvate has previously in preclinical studies been shown to be a sensitive method for diagnosing cancer and assessment of early treatment response in a variety of cancers [26]. Recently, a first-in-man study of 31 patients was conducted with the primary objective to assess the safety of hyperpolarized $^{13}$C-pyruvate in healthy subjects and prostate cancer patients. The study showed an elevated $^{13}$C-lactate/$^{13}$C-pyruvate ratio in regions of biopsy-proven prostate cancer [27]. With the emergence of hybrid PET/MR systems and the present study demonstrating feasibility of hyperPET, we therefore suggest that combined $^{18}$F-FDG-PET and $^{13}$C-pyruvate MRSI could be valuable in the clinical work-up of cancer patients. MRS imaging with $^{13}$C-pyruvate...
may therefore have clinical relevance as added information when used together with $^{18}$F-FDG-PET and provide better phenotyping of tumors. In addition, hyperpolarized $^{13}$C-pyruvate imaging may be the only feasible way to study glycolysis in tumors where $^{18}$F-FDG-PET is of little value as in prostate cancer (low $^{18}$F-FDG uptake and high bladder activity) and brain tumors (high physiological uptake in the brain).

With regard to early response monitoring in cancer treatment, the possibility exists that $^{13}$C-pyruvate can detect such effects earlier than $^{18}$F-FDG-PET. However, this remains to be answered through comparative PET and hyperpolarized MRSI studies. From both a clinical and basic science perspective, further comparison of PET and $^{13}$C-pyruvate-lactate conversion is needed to elucidate the differential information gained from the modalities. Previous preclinical comparison studies have been carried out on separate systems [28, 29], with a potential error arising from the time difference between the examinations and errors in positioning of the animal. However, the introduction of integrated PET/MR systems allows for single-session, simultaneous MRI and PET. At present such combined studies with hyperpolarized MRSI and PET remains to be performed.

With the current study carried out on a canine cancer patient with a liposarcoma and using a clinical PET/MRI scanner we have clearly demonstrated that concurrent DNP $^{13}$C-lactate/$^{13}$C-pyruvate CSI and $^{18}$F-FDG-PET imaging is feasible in a clinical setting. Future, systematic studies are needed to assess the clinical value of combining these modalities within oncology.

**Conclusion**

To our knowledge this is first study acquiring both DNP $^{13}$C-lactate/$^{13}$C-pyruvate CSI and $^{18}$F-FDG-PET using a combined PET/MR scanner. We propose that this new concept of simultaneous hyperpolarized $^{13}$C-imaging and $^{18}$F-FDG-PET may be highly valuable for image-based non-invasive phenotyping of tumors. Translation into humans of this technique will demonstrate whether it is of clinical value.

**Acknowledgements**

The financial support from the John and Birthe Meyer Foundation and the Capital Region of Denmark is gratefully acknowledged. Karin Staehr, Marianne Federspiel, Jakup Poulsen and Betina Senius Pedersen are acknowledged for invaluable technical assistance.

**Address correspondence to:** Dr. Andreas Kjaer, Department of Clinical Physiology, Nuclear Medicine & PET, KF-4012, Rigshospitalet, National University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Tel: + 45 3545 4011; Fax: + 45 3545 4015; E-mail: akjaer@sund.ku.dk

**References**

Hyperpolarized $^{13}$C-pyruvate and $^{18}$F-FDG-PET in cancer


